These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21185886)

  • 21. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
    Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
    J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity.
    Choi JY; Jang EH; Park CS; Kang JH
    Free Radic Biol Med; 2005 Mar; 38(6):806-16. PubMed ID: 15721991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methamphetamine- and 1-methyl-4-phenyl- 1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice.
    Itzhak Y; Martin JL; Ali SF
    Synapse; 1999 Dec; 34(4):305-12. PubMed ID: 10529724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropathological changes induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in male Swiss albino mice.
    Rajeswari A; Sabesan M
    Toxicol Ind Health; 2008 Apr; 24(3):189-94. PubMed ID: 18842698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis.
    Tandé D; Höglinger G; Debeir T; Freundlieb N; Hirsch EC; François C
    Brain; 2006 May; 129(Pt 5):1194-200. PubMed ID: 16481374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
    Callier S; Morissette M; Grandbois M; Pélaprat D; Di Paolo T
    Synapse; 2001 Aug; 41(2):131-8. PubMed ID: 11400179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
    Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
    J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
    Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
    Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter.
    Bezard E; Gross CE; Fournier MC; Dovero S; Bloch B; Jaber M
    Exp Neurol; 1999 Feb; 155(2):268-73. PubMed ID: 10072302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
    Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiating effect of the ATP-sensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo.
    Kou J; Klorig DC; Bloomquist JR
    Neurotoxicology; 2006 Sep; 27(5):826-34. PubMed ID: 16725203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.
    Pierri M; Vaudano E; Sager T; Englund U
    Neuropharmacology; 2005 Mar; 48(4):517-24. PubMed ID: 15755479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen receptors and lesion-induced response of striatal dopamine receptors.
    Al Sweidi S; Morissette M; Rouillard C; Di Paolo T
    Neuroscience; 2013 Apr; 236():99-109. PubMed ID: 23357113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP.
    Aguirre JA; Kehr J; Yoshitake T; Liu FL; Rivera A; Fernandez-Espinola S; Andbjer B; Leo G; Medhurst AD; Agnati LF; Fuxe K
    Brain Res; 2005 Feb; 1033(2):216-20. PubMed ID: 15694927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
    Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW
    Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presymptomatic MPTP Mice Show Neurotrophic S100B/mRAGE Striatal Levels.
    Viana SD; Fernandes RC; Canas PM; Silva AM; Carvalho F; Ali SF; Fontes Ribeiro CA; Pereira FC
    CNS Neurosci Ther; 2016 May; 22(5):396-403. PubMed ID: 26843141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of uptake of 1-methyl-4-phenylpyridinium ion and dopamine in striatal synaptosomes by tobacco smoke components.
    Carr LA; Basham JK; York BK; Rowell PP
    Eur J Pharmacol; 1992 May; 215(2-3):285-7. PubMed ID: 1396992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.